U.S. decision does not relate to Vascepa inCanada - Vascepa was granted 8 years of data exclusivity by
Health Canada upon approval - Vascepa patent estate could potentially extend protection in
Canada to 2039
HLS affirms that that this litigation and judgment do not impact VASCEPA in
- Geographies outside
the United States in which VASCEPA is sold and under regulatory review are not subject to this litigation and judgment; - VASCEPA was added to
Health Canada's Register of Innovative Drugs inJanuary 2020 and benefits from eight years of data protection untilDecember 2027 ; - VASCEPA is also the subject of numerous Canadian issued patents and pending patents that were not part of the
U.S. litigation and that could extend patent protection inCanada to 2039; and - No litigation is pending in
Canada regarding VASCEPA.
"As with the
To view Amarin's response to the court's ruling, please see their press release dated
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated
SOURCE
© Canada Newswire, source